Demographic and Clinical Characteristics (Table 1)  
- 305 patients were eligible for the study.  
- 236 patients (76.2%) were treated with Neo+Adj, 64 patients (20.9%) were treated with Neo, and 5 patients (1.6%) were treated with NOS.  
- The mean age at diagnosis was 56.7 years (SD 11.6).  
- The majority of patients were White (56.8%), followed by Black or African American (35.7%), and the least common were Asian (4.9%).  
- The majority of patients were diagnosed with stage II disease (66.6%).  
- The mean number of events per month among incident patients was 1.49 and 2.18, respectively.

HCRU (Table 2)  
- Mean monthly cost per patient was higher during Time 1 ($9,486) than Time 2 ($1,599).  
- Cost was primarily attributable to ISC ($5,305) and SAT ($4,464).  
- ED visits were the key cost component for both treatment groups during Time 2.

RESULTS

- The study was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
- This study reflects treatment and practice patterns only in US community oncology practices in the Definitive Oncology Dataset. Treatment patterns may differ in academic centers compared with community settings.
- Patients in the Definitive Oncology Dataset may differ from the general ESTNBC population in ways that may not be measurable.
- Some measurements may not be consistently available from patient records in the Definitive Oncology Database.